Review
doi: 10.1016/j.rdc.2004.01.003.
Consideration of the risk and treatment of tuberculosis in patients who have rheumatoid arthritis and receive biologic treatments
Affiliations
- PMID: 15172039
- DOI: 10.1016/j.rdc.2004.01.003
Item in Clipboard
Review
Consideration of the risk and treatment of tuberculosis in patients who have rheumatoid arthritis and receive biologic treatments
Rheum Dis Clin North Am.
2004 May.
Abstract
Evidence supports the association of tuberculosis (TB) with tumor necrosis factor inhibitor therapy in patients who have rheumatoid arthritis. There seem to be differential risks of TB with the currently available inhibitors. Screening for latent TB infection with purified protein derivative is indicated for patients who are being considered for treatment; it seems to be effective in reducing the occurrence of TB in treated patients.
Similar articles
-
Disseminated tuberculosis secondary to adalimumab.Am J Ther. 2012 Jul;19(4):e139-40. doi: 10.1097/MJT.0b013e3181ee7391. Am J Ther. 2012. PMID: 20838203
-
Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers.J Rheumatol. 2007 Apr;34(4):706-11. Epub 2007 Feb 15. J Rheumatol. 2007. PMID: 17309133
-
Safety of etanercept in patients at high risk for mycobacterial tuberculosis infections.J Rheumatol. 2009 May;36(5):914-7. doi: 10.3899/jrheum.081041. Epub 2009 Mar 30. J Rheumatol. 2009. PMID: 19332623
-
Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor.Nat Clin Pract Rheumatol. 2006 Nov;2(11):602-10. doi: 10.1038/ncprheum0336. Nat Clin Pract Rheumatol. 2006. PMID: 17075599 Review.
-
The risk of infections with biologic therapies for rheumatoid arthritis.Semin Arthritis Rheum. 2010 Apr;39(5):327-46. doi: 10.1016/j.semarthrit.2008.10.002. Epub 2008 Dec 31. Semin Arthritis Rheum. 2010. PMID: 19117595 Review.
Cited by
-
Dual mycobacterial infection in the setting of leflunomide treatment for rheumatoid arthritis.Ann Rheum Dis. 2007 Feb;66(2):277. doi: 10.1136/ard.2006.056283. Ann Rheum Dis. 2007. PMID: 17242021 Free PMC article. No abstract available.
-
Vasculitis induced by tumor necrosis factor-targeted therapies.Curr Rheumatol Rep. 2008 Dec;10(6):442-8. doi: 10.1007/s11926-008-0072-z. Curr Rheumatol Rep. 2008. PMID: 19007533 Review.
-
Poor agreement between QuantiFERON-TB Gold test and tuberculin skin test results for the diagnosis of latent tuberculosis infection in rheumatoid arthritis patients and healthy controls.Korean J Intern Med. 2014 Jan;29(1):76-84. doi: 10.3904/kjim.2014.29.1.76. Epub 2014 Jan 2. Korean J Intern Med. 2014. PMID: 24574836 Free PMC article. Clinical Trial.
-
Pleural Tuberculosis following Infliximab Therapy for Ankylosing Spondylitis.J Pharmacol Pharmacother. 2017 Jan-Mar;8(1):41-43. doi: 10.4103/jpp.JPP_174_16. J Pharmacol Pharmacother. 2017. PMID: 28405137 Free PMC article.
-
Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis.Ann Rheum Dis. 2006 Jul;65(7):889-94. doi: 10.1136/ard.2005.043166. Epub 2006 Jan 26. Ann Rheum Dis. 2006. PMID: 16439435 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
